Trinity Biotech
TRIB
52 hedge funds and large institutions have $81.5M invested in Trinity Biotech in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.09% less ownership
Funds ownership: 3.15% → 3.06% (-0.09%)
7% less funds holding
Funds holding: 56 → 52 (-4)
9% less capital invested
Capital invested by funds: $89.6M → $81.5M (-$8.1M)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $73K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$997K |
| 2 |
Morgan Stanley
New York
|
+$855K |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$547K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$453K |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$452K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$1.09M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.06M |
| 3 |
D.E. Shaw & Co
New York
|
-$967K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$879K |
| 5 |
CSC
Cove Street Capital
El Segundo,
California
|
-$603K |
TRIB Hedge Fund Activity: Q3 2017 in Review
52 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2017, worth a combined $81.5M — down 9% from $89.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRIB and 4 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 12 added.
The largest buyer was Senvest Management, adding an estimated $997K. The largest seller was Royce & Associates, exiting entirely with an estimated $1.09M sold.
- 52 institutional investors held Trinity Biotech (TRIB) as of Q3 2017, down from 56 in Q2 2017.
- Funds reported $81.5M of Trinity Biotech stock for Q3 2017, down 9% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q3 2017 and 7 closed out, a net change of -3 holders.
- The largest Trinity Biotech buyer in Q3 2017 was Senvest Management, an estimated $997K added.
- The largest Trinity Biotech seller in Q3 2017 was Royce & Associates, an estimated $1.09M sold.
Based on aggregated 13F filings for Q3 2017.